Early intervention can prevent sexual transmission of HIV

Image
IANS Ottawa
Last Updated : Jul 21 2015 | 4:57 PM IST

Starting antiretroviral therapy early is highly effective in preventing sexual transmission of the virus in heterosexual couples where one person is HIV-infected and the other is not, according to results of a decade-long clinical trial involving participants from India, among other countries.

The findings were presented on Monday at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2015) in Vancouver, Canada.

"The study now makes crystal clear that when an HIV-infected person takes antiretroviral therapy that keeps the virus suppressed, the treatment is highly effective at preventing sexual transmission of HIV to an uninfected heterosexual partner," said Anthony Fauci, director National Institute of Allergy and Infectious Diseases in the US.

"For heterosexuals who can achieve and maintain viral suppression, the risk to their partners is exceedingly low," Fauci added.

Beginning in April 2005, the study enrolled 1,763 heterosexual couples ages 18 or older in Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, the United States and Zimbabwe.

Each couple included one partner with HIV infection and one without. Infected participants were assigned at random either to start antiretroviral therapy right away, while their immune system was relatively healthy, or to delay starting treatment until their immune system weakened or they developed an AIDS-defining illness, consistent with WHO (World Health Organization) guidelines at the time.

All participants received condoms and counselling on how to protect their partners from sexual transmission of HIV. At the end of the study, 1,171 couples remained in the trial. Starting antiretroviral therapy early reduced HIV transmission by 93 percent over the course of the study, the findings showed.

Only eight cases of HIV transmission occurred in uninfected partners of HIV-infected participants who received antiretroviral therapy.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 21 2015 | 4:46 PM IST

Next Story